Recent developments include strategic collaborations to advance regenerative medicine treatments, leadership appointments, financing to support clinical trials, and periodic financial results disclosures.

• Announced a strategic collaboration with Children’s Hospital Capital Institute of Pediatrics in Beijing, China to advance treatment for esophageal atresia [N1].
• Appointed Mao Zhang to the Board of Directors in August 2024 [N2].
• Announced $5 million financing to continue clinical trials in August 2024 [N3].
• Reported first quarter 2024 financial results and recent business highlights in May 2024 [N4].
• Reported fourth quarter and full year 2023 financial results and recent business highlights in April 2024 [N5].
• Established a research collaboration with the McGowan Institute for Regenerative Medicine at the University of Pittsburgh to study colon repair following colectomy in December 2023 [N6].
• Established a collaboration with a renowned professor/physician to repair and regenerate the uterus in December 2023 [N7].
• Reported third quarter 2023 financial results in November 2023 [N8].

The company’s strategic collaborations with prominent hospitals and research institutes, such as the Children’s Hospital Capital Institute of Pediatrics in Beijing and the McGowan Institute for Regenerative Medicine, support advancement of its regenerative medicine pipeline. The exclusive global distribution agreement with Health Regen for consumer health products provides a clear channel for revenue generation. Recent financing of $5 million supports ongoing clinical trials, which are critical milestones for product development. The company’s focus on orphan diseases and regenerative therapies addresses unmet medical needs, potentially enabling future market opportunities.

The company has a history of recurring losses and an accumulated deficit exceeding $106 million as of December 31, 2025. The going concern note in the audited financial statements highlights substantial doubt about the company’s ability to continue without additional financing. The company depends on single-source suppliers for critical components, which may pose supply chain risks. Regulatory approval processes are complex and uncertain, with ongoing compliance requirements. The company’s consumer health product revenues remain modest, and the regenerative biotech segment has yet to generate product revenue. Execution risks in clinical development and commercialization remain significant.

Harvard Apparatus Regenerative Technology’s moat is derived from its proprietary regenerative medicine technologies and its exclusive global distribution agreement for consumer health products. The company’s collaborations with leading research institutions and hospitals provide access to specialized expertise and clinical trial capabilities. Its proprietary automatic cell seeder, bioreactor control, and acquisition systems rely on single-source suppliers, which may create some supply chain dependencies. The company’s regulatory approvals, including orphan disease designation for its lead product in Europe, contribute to barriers to entry. However, the company operates in a highly regulated and competitive biotechnology sector with significant development and commercialization risks.

• Going Concern and Financing Risk: The company has recurring losses, an accumulated deficit, and requires additional financing to fund operations, raising substantial doubt about its ability to continue as a going concern [S1].
• Regulatory and Compliance Risk: The company’s products and manufacturing processes are subject to FDA and foreign regulatory approvals and ongoing compliance, which can be costly and may delay or restrict market access [S1].
• Supply Chain Risk: Dependence on single-source suppliers for critical hardware components may lead to delays or disruptions in product development and manufacturing [S1].
• Clinical Development Risk: The company’s regenerative biotech segment is in clinical trial stages, with inherent risks related to trial outcomes, regulatory approvals, and commercialization [S1][N3].
• Market and Commercialization Risk: Consumer health product revenues are currently modest and primarily generated in Asia; expansion and sustained growth depend on effective distribution and market acceptance [S1].

• Harvard Apparatus Regenerative Technology, Inc. operates two reportable segments: Regenerative Biotech focused on regenerative medicine treatments in the U.S., and Consumer Health Products focused on dietary supplements marketed primarily in Asia [S1].
• All revenue is generated in Asia from Consumer Health Products, with product revenue of $704,000 in 2025, up from $430,000 in 2024 [S1].
• The company entered an exclusive global distribution agreement with Health Regen in October 2024 for its Consumer Health Products [S1].
• Revenue recognition for sales to Health Regen occurs when goods are made available for transfer [S1].
• Cost of sales primarily includes purchase price of consumer products, taxes, and shipping costs [S1].
• Research and development expenses relate mainly to regenerative biotech activities and are expensed as incurred, totaling $2.65 million in 2025 [S1].
• Sales and marketing expenses decreased to $67,000 in 2025 from $554,000 in 2024, reflecting changes in marketing focus [S1].
• General and administrative expenses were $4.25 million in 2025 [S1].
• The company reported a net loss of $6.87 million for the year ended December 31, 2025, with basic and diluted net loss per share of $0.42 [S1].
• As of December 31, 2025, the company had cash and cash equivalents of $1.35 million and short-term investments of $1.2 million, with a current ratio of 1.19 and cash ratio of 1.66 [S1].
• The company has an accumulated deficit of $106.6 million as of December 31, 2025 [S1].
• Deferred revenue of $252,000 as of December 31, 2025, primarily represents advance payments for consumer health products to be recognized within the next fiscal quarter [S1].
• The company has ongoing clinical trial activities supported by contracts and prepaid expenses, including a $5 million financing announced in August 2024 to continue clinical trials [N3][S1].
• Recent strategic collaborations include partnerships with Children’s Hospital Capital Institute of Pediatrics in Beijing to advance treatment for esophageal atresia, and research collaborations with the McGowan Institute for Regenerative Medicine and a renowned professor/physician to study colon repair and uterus regeneration [N1][N6][N7].
• The company appointed Mao Zhang to its Board of Directors in August 2024 [N2].
• The company’s auditor has identified share-based compensation expense recognition related to performance-based awards as a critical audit matter due to the complexity and judgment involved [S1].
• The company’s operations include manufacturing and distribution facilities, with a lease for office, research, and manufacturing space in Holliston, MA, through August 2027 [S1].
• The company’s consumer health products are sold primarily through a third-party online store and distributed globally via Health Regen [S1].
• The company’s regulatory environment involves FDA and foreign regulatory approvals, with risks related to compliance and market access [S1].
• The company depends on single-source suppliers for certain hardware components critical to its proprietary systems [S1].
• The company’s financial statements include a going concern explanatory paragraph citing recurring losses, accumulated deficit, and the need for additional financing [S1].